Gene therapy is on the rise. As clinical success, innovation and investment in this area strengthens, Precedence Research predicts that the cell and gene therapy market will grow at a CAGR of 22 percent by 2030. Additionally, the FDA expects it will approve 10 to 20 cell and gene therapy products a year starting in 2025, based on the current clinical pipeline. Minh Hong, Ph.D., head of commercial, viral vector CDMO services with MilliporeSigma, says that this growth is a reflection of the vast potential that gene therapy offers patients.
